Downregulation of PGI in the production of adenosine
By downregulating pgi expression or activity, recombinant microbial strains SHG60△pgi and SHG64 were constructed, optimizing the carbon metabolism of Bacillus subtilis, solving the problem of low adenosine yield in microbial fermentation, and achieving high-yield and high-efficiency industrial production.
Patent Information
- Application Number
- CN202410467221.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-18
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-04-18
AI Technical Summary
Existing microbial fermentation methods for producing adenosine have limited yields and are complex to operate, making it difficult to meet industrial needs.
By downregulating the expression or activity of pgi, recombinant microbial strains such as SHG60△pgi and SHG64 were constructed to optimize the carbon metabolism pathway of Bacillus subtilis and increase adenosine production.
It achieves increased adenosine yield, shortened fermentation cycle, and improved production intensity, making it suitable for the industrial production of adenosine.
Smart Images

Figure CN118360309B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to the application of down-regulating PGI in producing adenosine. Background Art
[0002] Adenosine, also known as adenine nucleoside, is a compound whose full name is 9-β-D-ribofuranosyl adenine. In biology, adenosine is often abbreviated as "AR". It refers to a compound formed by the N-9 of adenine and the C-1 of D-ribose connected by a β-glycosidic bond. Its chemical formula is C 10 H 13 N5O4, with a molecular weight of 267.24. Adenosine belongs to the class of endogenous purine nucleosides and is found throughout human cells. It can directly enter the myocardium and undergo phosphorylation to produce adenosine monophosphate, participating in myocardial energy metabolism. It also dilates coronary arteries and increases blood flow. Adenosine has physiological effects on the cardiovascular system and many other systems and tissues of the body. Adenosine is an important intermediate used in the synthesis of drugs such as adenosine triphosphate (ATP), adenine, adenylic acid, adenosine arabinoside, coenzyme A (COASH), and its derivative, cyclic adenosine monophosphate (CAMP). Adenosine is used to treat conditions such as coronary artery disease, angina pectoris, arteriosclerosis, and hypertension. It can also be used as an additive in foods and health supplements, and has promising market prospects.
[0003] Adenosine can be produced by chemical and biosynthetic methods. Due to increasingly stringent environmental requirements in recent years, the chemical method has gradually lost its dominant position. Biosynthetic methods include RNA degradation and fermentation. However, the RNA degradation method has a long and complex process. Furthermore, of the four nucleosides produced during RNA degradation, adenosine only accounts for one-quarter. This not only limits adenosine production but also makes extraction and separation difficult, increasing costs. Consequently, this method has been largely phased out.
[0004] Microbial fermentation for adenosine production involves treating the starting strain with physical or chemical methods to alter its metabolic pathways or genetic markers, or by improving fermentation conditions or fermentation medium composition to increase adenosine production. Strains used for adenosine production by fermentation include Escherichia coli, Bacillus pumilus, yeast, and Bacillus subtilis, with Bacillus subtilis being the most commonly used. Fermentation-based adenosine production offers advantages such as low production costs, mild reaction conditions, and a wide range of raw materials. However, the strains currently used in industrial production are mostly mutagenic strains, resulting in limited yield increases and some of the strains' genetic markers being difficult to stably propagate.
[0005] Therefore, there is an urgent need to find a method that can increase the yield of adenosine produced by microbial fermentation, is easy to operate, and can be applied to industrial production. Summary of the Invention
[0006] To address the above issues, the present invention provides the use of down-regulating PGI in adenosine production. This invention provides a method for increasing adenosine production by down-regulating the expression or activity of PGI, providing a reference for modifying carbon metabolism in Bacillus subtilis to produce nucleoside products. The recombinant microorganism provided by the present invention can be used for the industrial production of adenosine, achieving higher yields, a shorter fermentation cycle, high production intensity, and ease of operation.
[0007] the term:
[0008] 1. Recombinant microorganism: Unless otherwise specified, the Chinese name "recombinant microorganism" in this invention refers to a microorganism that has been artificially manipulated; such artificial manipulation includes but is not limited to gene knockout, gene suppression, gene silencing, gene insertion, gene mutation, exogenous expression or overexpression of genes, and other technical means in the art that can achieve genetic manipulation.
[0009] 2. Seed solution: Unless otherwise specified, the Chinese name "seed solution" in the present invention refers to the microbial culture solution containing a certain number of microorganisms, with good vitality and quality, obtained after the microorganisms are activated on the slant surface of a test tube, cultured on a flat or shake bottle, or cultured in a seed tank in stages.
[0010] 3. Exogenous expression or overexpression: When used with respect to the present invention, this term should be broadly construed to include any increase in protein expression (including nucleic acid expression) compared to the expression level of one or more proteins (including one or more nucleic acids encoding one or more proteins) of the parent microorganism under the same conditions. It should not be construed to mean that the protein (or nucleic acid) is expressed at any particular level.
[0011] 4. Vector: This term should be broadly considered to include any nucleic acid (including DNA and RNA) suitable for use as a vehicle for transferring genetic material into cells, including plasmids, viruses (including bacteriophages), cosmids, and artificial chromosomes. A vector may include one or more regulatory elements, an origin of replication, a multiple cloning site, and / or a selectable marker.
[0012] 5. Conventions regarding protein and gene names: The English protein names involved in the present invention all have their first letters capitalized; the English gene names involved in the present invention all have their first letters lowercase.
[0013] In order to achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:
[0014] In one aspect, the present invention provides a use of pgi in producing adenosine, wherein the use increases the production of adenosine by downregulating the expression or activity of pgi.
[0015] Specifically, the application utilizes a recombinant microorganism with downregulated pgi to ferment and produce adenosine or utilizes its whole cell product to catalyze a substrate to produce adenosine.
[0016] Preferably, the recombinant microorganism is constructed by knocking out or weakening pgi using Bacillus subtilis SHG60 as the starting strain.
[0017] Further preferably, the deposit number of the Bacillus subtilis SHG60 is CGMCC No.29400.
[0018] Further preferably, the knockout comprises transforming the pHB508 plasmid into the SHG60 strain to construct the pgi knockout strain SHG60Δpgi.
[0019] Further preferably, the attenuation comprises transforming the pHB553 plasmid into the strain SHG60Δpgi to construct the pgi-attenuated strain SHG64, which has a deposit number of CGMCC No.29167.
[0020] Still more preferably, the nucleotide sequence of the pHB553 plasmid is shown in SEQ ID NO: 1.
[0021] Preferably, the whole-cell product includes culture medium, cell lysate, the supernatant of the cell lysate, and the precipitate of the cell lysate. It should be noted that in future technological developments, new technologies for the manipulation of whole-cell products and their specific product types should also be within the scope of the above-mentioned claims, as they do not deviate from the inventive concept of the present invention.
[0022] Specifically, the application also includes application in the preparation of feed, food, health products or medicines containing adenosine.
[0023] On the other hand, the present invention provides a strain, which is SHG60, which was deposited in the General Microbiology Center of the China Culture Collection Administration on December 25, 2023. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 29400.
[0024] On the other hand, the present invention provides a recombinant microorganism, which is constructed by knocking out or weakening pgi using SHG60 (CGMCC No. 29400) as the starting strain.
[0025] Specifically, the recombinant microorganism includes strain SHG60Δpgi or strain SHG64.
[0026] Preferably, the strain SHG60Δpgi is constructed by knocking out pgi.
[0027] Preferably, the strain SHG64 is constructed by weakening pgi.
[0028] Preferably, the strain SHG64 is Bacillus subtilis, which was deposited in the General Microbiology Center of the China Culture Collection Administration on November 29, 2023. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 29167.
[0029] In another aspect, the present invention provides a method for producing adenosine, including but not limited to using the above-mentioned recombinant microorganism to ferment and produce adenosine or using the above-mentioned recombinant microorganism whole cell product to catalyze a substrate to produce adenosine.
[0030] Specifically, the whole-cell product includes, but is not limited to, culture fluid, cell lysate, the supernatant of the cell lysate, and the precipitate of the cell lysate. It should be noted that in future technological developments, new technologies for the manipulation of whole-cell products and their specific product types should also be within the scope of the above-mentioned claims, as they do not deviate from the inventive concept of the present invention.
[0031] The positive and beneficial effects of the present invention are:
[0032] (1) The present invention discovered that pgI exhibits different effects at different stages of constructing adenosine genetically engineered strains. This invention demonstrates the application of pgI knockout or attenuation in adenosine production, providing a reference for modifying carbon metabolism in Bacillus subtilis to produce nucleoside products.
[0033] (2) The recombinant microorganisms described in the present invention are used to produce adenosine, which has a higher yield, a short fermentation cycle, and a high production intensity, and can be used for large-scale industrial production of adenosine.
[0034] Preservation Instructions
[0035] Biological material (strain name): Bacillus subtilis SHG60;
[0036] Classification and nomenclature: Bacillus subtilis;
[0037] Deposit number: CGMCC No.29400;
[0038] Depository: General Microbiology Center, China Culture Collection Administration;
[0039] Deposit date: December 25, 2023;
[0040] Collection address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0041] Biological material (strain name): Bacillus subtilis SHG64;
[0042] Classification and nomenclature: Bacillus subtilis;
[0043] Deposit number: CGMCC No.29167;
[0044] Depository: General Microbiology Center, China Culture Collection Administration;
[0045] Deposit date: November 29, 2023;
[0046] Collection address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 This is a comparison chart of HPLC peaks.
[0048] Figure 2 This is a nucleic acid gel image verifying pHB508 enzyme digestion.
[0049] Figure 3 This is the fermentation result of pgi knockout.
[0050] Figure 4 This is the fermentation result of weakened PGI. DETAILED DESCRIPTION
[0051] The present invention will be further described in detail below with reference to specific examples. The following examples are not intended to limit the present invention but are merely intended to illustrate the present invention. The experimental methods used in the following examples are generally based on conventional conditions unless otherwise specified. The materials and reagents used in the following examples are all commercially available unless otherwise specified.
[0052] Example 1 Method for producing adenosine by shake flask fermentation
[0053] 1. Reagents
[0054] (1) LB medium: Each liter of medium contains 5 g of yeast powder, 10 g of sodium chloride, and 10 g of peptone, and the volume is adjusted to 1 L with deionized water (author J. Shambrook, translated by Huang Peitang, Molecular Cloning Guide 2002, 1595).
[0055] The above solution is sterilized by high pressure steam at a sterilization temperature of 121° C. for 20-30 min.
[0056] (2) Fermentation medium: per liter of culture medium, 50 g of glucose, 5 g of corn steep liquor powder, 5 g of yeast extract, 10 g of monosodium glutamate, 5 g of ammonium sulfate, 1 g of potassium dihydrogen phosphate, 0.4 g of magnesium sulfate heptahydrate, and 20 g of calcium carbonate were dissolved in deionized water, the pH was adjusted to 7.0, and the volume was adjusted to 1 L with deionized water.
[0057] The above solution was sterilized by high-pressure steam at 121°C for 20-30 minutes. Meanwhile, empty shake flasks were prepared, and 0.4 g of calcium carbonate was weighed into each flask, with a final calcium carbonate concentration of 20 g / L during fermentation. The solution was sterilized at 121°C for 20-30 minutes and set aside.
[0058] 2. Instruments: constant temperature shaker, constant temperature incubator.
[0059] 3. Shake flask fermentation method:
[0060] (1) Inoculate the recombinant strain into 3 mL of LB medium containing antibiotics and culture at 37°C in a shaker at 250 rpm.
[0061] (2) After 16 h of culture, 500 μL of the seed solution was transferred to 1.5 mL of LB liquid medium containing antibiotics and cultured at 37°C with a shaker at 250 rpm for 4 h.
[0062] (3) Transfer all 2 mL of secondary seeds into a shake flask containing 18 mL of fermentation medium and culture in a shaker at 37°C and 250 rpm.
[0063] (4) After fermentation for about 45 hours, take 0.1 mL of fermentation broth and dilute it with 2.9 mL of 30 mM dilute hydrochloric acid, and then measure the OD of the fermentation broth. 600 .
[0064] (6) The remaining fermentation broth was diluted with 0.2 M NaOH for a certain multiple, centrifuged (12000 rpm, 1 min), and the supernatant was filtered through a 0.22 μm filter membrane and then detected by HPLC.
[0065] 4. HPLC determination of adenosine in fermentation broth
[0066] The HPLC parameters are as follows:
[0067] Chromatographic column: XBridge C18 4.6*150mm 5μm;
[0068] Mobile phase A: methanol;
[0069] Mobile phase B: 10 mM ammonium acetate or PBS (pH 4.0);
[0070] Column temperature: 30°C;
[0071] Initial flow rate: 1.0 mL / min;
[0072] Detection wavelength: 254nm.
[0073] Table 1 Gradient
[0074] Time (mins) Phase A (% v / v) Phase B (% v / v) Flow rate (mL / min) 0.01 2 98 1.0 6.00 7 93 1.2 8.00 28 72 1.2 8.50 2 98 1.2 11.00 2 98 1.2
[0075] HPLC spectrum such as Figure 1 As shown, the peak time of hypoxanthine is 3.1 min, the peak time of adenine is 5.0 min, the peak time of inosine is 5.6 min, and the peak time of adenosine is 9.1 min.
[0076] Example 2 Construction of pgi knockout plasmid
[0077] (1) Using the genome of Bacilllus subtilis 168 as a template, the 1099 bp upstream homology arm of pgi-homL1 was obtained by PCR with primer pair YHB1586 and YHB1587.
[0078] (2) Using the genome of Bacilllus subtilis 168 as a template, PCR was performed with primer pair YHB1588 and YHB1589 to obtain the 1134 bp downstream homology arm of pgi-homR1. The sequences of the primers used in (1) and (2) above are shown in Table 2
[0079] Table 2 Primer sequences
[0080] Primer name Serial number Primer sequence 5'→3' YHB1586 SEQ ID NO: 2 gggcctcttcgctattacgccagcaaggcataggactttgcagag YHB1587 SEQ ID NO: 3 acatttgtattcgtactcaatcgcattgcttgtccctccataacg YHB1588 SEQ ID NO: 4 tgtatgctaaacgagggtattatgtgtgagaaagctgactggcatt YHB1589 SEQ ID NO: 5 tttcacacaggaaacagctatgaccaagctgacacttgatcagcatg
[0081] (3) Referring to the suicide plasmid construction method described in patent CN113755412B, the pgi-homL1 upstream homology arm and the pgi-homR1 downstream homology arm obtained above were recombined into a vector containing Escherichia coli ori, kan operon, upp operon and Em (Bacillus) components by seamless cloning (GBclonart seamless cloning kit, Suzhou Shenzhou Gene Co., Ltd., catalog number GB2001) to obtain the pgi knockout plasmid pHB508. EcoRI (Thermo Scientific, catalog number FD0274) enzyme digestion confirmed that two bands of 1087 bp and 5792 bp were obtained, indicating that the plasmid size was correct. The nucleic acid gel image of pHB508 plasmid enzyme digestion verification is shown in FIG. Figure 2 .
[0082] Example 3 pgi knockout and shake flask fermentation verification
[0083] (1) Strain background: BF9 is a genetically engineered strain preserved in our laboratory, derived from strain BF3 (deposit number CGMCC No. 19574) in patent CN113755412B; SHG60 is a strain that integrates different copies of purine operon genes and PPP pathway genes from different sources based on the BF9 strain, with a deposit number of CGMCC No. 29400.
[0084] (2) pgi knockout in BF9 and SHG60 strains: Referring to the transformation method described in patent CN113755412B, the pHB508 plasmid in Example 2 was transformed into BF9 and SHG60 strains, respectively, to obtain pgi knockout strains BF9Δpgi and SHG60Δpgi.
[0085] (3) Referring to the shake flask fermentation method in Example 1, BF9, BF9Δpgi, SHG60 and SHG60Δpgi were fermented to verify the effect of pgi knockout on adenosine production. The results are shown in Figure 3 After knocking out pgi in BF9, the strain grew poorly and the adenosine production was also low; after knocking out pgi in SHG60, there was little effect on the strain growth, and the adenosine production was increased. That is, after integrating the purine pathway and PPP pathway genes, knocking out pgi is conducive to the flow of carbon metabolism to adenosine.
[0086] Example 4 Construction of pGI-weakened plasmid
[0087] (1) According to Yang 2011 (Yang, H., Liao, Y., Wang, B., Lin, Y., & Pan, L. (2011). Complete Genome Sequence of Bacillus amyloliquefaciens XH7, Which Exhibits Production of Purine Nucleosides. Journal of Bacteriology, 193, 5593-5594.), it was verified that the enzyme activity of pGI from Bacillus amyloliquefaciens XH7 was much lower than that of pGI from Bacillus subtilis 168. Therefore, pGI from Bacillus amyloliquefaciens XH7 was applied to adenosine production. The pGI mutant mentioned below refers to pGI from Bacillus amyloliquefaciens XH7.
[0088] (2) Using the genome of Bacilllus subtilis 168 as a template, the 1099 bp upstream homology arm of pgi homL2 was obtained by PCR with primer pair YHB1721 and YHB1722.
[0089] (3) Using the Bacillus amyloliquefaciens genome as a template, a 1353 bp pgi mutant fragment was obtained by PCR using primer pair YHB1725 and YHB1726.
[0090] (4) Using the genome of Bacilllus subtilis 168 as a template, PCR was performed with primer pair YHB1723 and YHB1724 to obtain the 1161 bp downstream homology arm of pgi-homR2.
[0091] (5) Using the Bacillus subtilis thermosensitive plasmid pBK85 as a vector, the thermosensitive integration plasmid pHB553 (nucleic acid sequence see SEQ ID NO: 1) was constructed according to the plasmid construction method described in patent CN113755412B. EcoRI enzyme digestion verification resulted in three bands of 1831 bp, 2244 bp, and 4193 bp, indicating that the plasmid size was correct.
[0092] Table 3 Primer sequences
[0093] Primer name Serial number Primer sequence 5'→3' YHB1721 SEQ ID NO: 6 gtatgatatcagtacatgcttgggaaggcataggactttgcagag YHB1722 SEQ ID NO: 7 gagtaatcaaagcgtacatgcgtcattgc YHB1723 SEQ ID NO: 8 ttgaaaaacgccttgaaaaataatgtgagaaagctgactggc YHB1724 SEQ ID NO: 9 gataataagggtaactattgccgttacggccgtctaaacagcagaac YHB1725 SEQ ID NO: 10 atgacgcatgtacgctttgattactc YHB1726 SEQ ID NO: 11 ttatttttcaaggcgtttttcaagctctg
[0094] Example 5: Weakening of pgi and verification of shake flask fermentation
[0095] (1) Referring to the transformation method described in patent CN113755412B, the pHB553 plasmid in Example 4 was transformed into the BF9Δpgi and SHG60Δpgi strains, respectively, to obtain the pgi-attenuated strains BF9Δpgi::pgi mutant and SHG60Δpgi::pgi mutant.
[0096] (2) Referring to the shake flask fermentation method in Example 1, BF9, BF9Δpgi::pgi mutant, SHG60 and SHG60Δpgi::pgi mutant were fermented to verify the effect of pgi weakening on adenosine production. The results are shown in Figure 4 After the weakening of BF9 pgi, the strain growth was still poor and the adenosine production was also low; after the weakening of SHG60 pgi, it had little effect on the strain growth, and the adenosine production increased more significantly, that is, after the integration of the purine pathway and PPP pathway genes, the weakening of pgi was more conducive to the flow of carbon metabolism to adenosine.
[0097] (3) The SHG60△pgi::pgi mutant in (2) above was named SHG64, and the classification name of the genetically engineered strain was Bacillus subtilis. The strain was deposited on November 29, 2023 at the General Microbiology Center of the China Culture Collection Administration, address: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Postal Code: 100101, China, with the deposit number CGMCC No. 29167.
[0098] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.
Claims
1. The use of pgi in the production of adenosine, characterized in that: The application increases the production of adenosine by downregulating the expression or activity of pgi; The application utilizes a recombinant microorganism with downregulated pgi to ferment and produce adenosine; The recombinant microorganism is constructed by knocking out or weakening pgi using Bacillus subtilis SHG60 as a starting strain, and the deposit number of the Bacillus subtilis SHG60 is CGMCC No.29400.
2. The use according to claim 1, characterized in that: The strain obtained by the weakened pgi construction is Bacillus subtilis SHG64, and its deposit number is CGMCC No.29167.
3. The use according to claim 1, characterized in that: The application also includes application in preparing feed, food or medicine containing adenosine.
4. The use according to claim 3, characterized in that: The application also includes application in preparing health products containing adenosine.
5. A recombinant microorganism, characterized in that The recombinant microorganism is constructed by knocking out or weakening pgi using Bacillus subtilis SHG60 as a starting strain, and the deposit number of the Bacillus subtilis SHG60 is CGMCC No.29400.
6. The recombinant microorganism according to claim 5, characterized in that The recombinant microorganism is Bacillus subtilis SHG64, and its deposit number is CGMCC No.29167.
7. A method for producing adenosine, characterized in that: The method utilizes the recombinant microorganism described in any one of claims 5-6 to produce adenosine by fermentation.
Citation Information
Patent Citations
High-yield acetyl-glucosamine recombinant bacillus subtilis and construction method thereof
CN106148260A
Bacillus subtilis, recombinant bacillus subtilis and application thereof
CN114958693A
